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The granting of staff privileges to physicians is an important
mechanism to ensure quality care. The Joint Commission
requires that medical staff privileges be based on
professional criteria specified in medical staff bylaws.
Physicians are charged with defining the criteria that
constitute professional competence and with evaluating
their peers accordingly. With the evolution of transcatheter
valve therapy, an important opportunity arises for both car-
diologists and surgeons to come together to identify the
criteria for performing these procedures. The Society for
Cardiovascular Angiography and Interventions (SCAI),
American Association for Thoracic Surgery (AATS),
American College of Cardiology (ACC), and The Society
for Thoracic Surgeons (STS) have therefore joined together
to provide recommendations for institutions to assess their
potential for instituting and/or maintaining a transcatheter
valve program. Since transcatheter valve therapy is in its
infancy, there are few data upon which to base these
recommendations. Therefore, many are based on expert
consensus. As the procedures evolve, technology changes,
experience grows, and more data accumulate, there will
certainly be a need to update these recommendations.
However, with the FDA having just approved these devices,
the writing committee and participating societies believe
that the recommendations listed in this report serve as an
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The Journal of Thoracic and Cathat these new valve therapies are best performed using a
team approach, these credentialing criteria may be best
applied at the institutional level.
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Clinical Guidelines Tommaso et alSCAI, AATS, ACC, and STS believe that adherence to
these recommendations will maximize the chances that
these therapies will become a successful part of the
armamentarium for treating valvular heart disease in the
United States. In addition, these recommendations will
hopefully facilitate optimum quality during the delivery
of this therapy, which will be important to the development
and implementation of future, less invasive approaches to
structural heart disease.
INTRODUCTION
Fueled by the development of new technologies, treat-
ment of valvular heart disease by transcatheter techniques
has become part of the armamentarium of cardiac pro-
viders, enabling less invasive treatment for patients previ-
ously treatable only with open-heart surgery or, in many
cases, not treatable at all. Recognition from the medical
community of the applicability, effectiveness, and practi-
cality of catheter-based transcatheter valve therapies has
further increased interest in these treatments. Training
program content, standards, credentialing, and board cer-
tifications for cardiac surgical procedures and percuta-
neous coronary intervention are well developed, but
there is no such structure in the field of percutaneous
structural or valvular heart disease therapies. The purpose
of this article is to outline criteria for operator and insti-
tutional requirements, to enable institutions and providers
to participate responsibly in this new and rapidly devel-
oping field.
The emergence of transcatheter valve repair and im-
plantation has been facilitated by innovative devices,
rapidly developing techniques, and careful patient
selection. The combination of interventional skills,
equipment, collaborative clinical management, surgical
approaches, techniques, and decision-making distinguish
the qualifications to participate in this field as unique, as
does the complexity of the patients requiring these ther-
apies.2,3 Given both the high-risk nature of these catheter
interventions and the availability of established
alternative treatment options using traditional surgical
approaches, several considerations are important for in-
stitutions and operators planning to implement these
new technologies.
Defining operator and institutional requirements for these
novel therapies is an important first step to ensuring their
optimal implementation.
Establishing a structural heart disease intervention
therapy program requires several key components
(Table 1). The defining principle is that this effort is a joint,
institutionally based activity for cardiologists and cardiac
surgeons.4 Thus, the specialty that provides some of these
components will vary from program to program. A trans-
catheter valve therapy program that uses only one specialty
is fundamentally deficient, and valve therapy programs388 The Journal of Thoracic and Cardiovascular Surgshould not be established without this multidisciplinary
partnership. Comprehensive multidisciplinary teams
(MDT) are, therefore, required for transcatheter valve
therapies and structural interventional programs.
KNOWLEDGE BASE AND SKILLS
The critical cornerstone of a transcatheter valve program
is a formal, collaborative effort between interventional car-
diologists and cardiac surgeons. This element is essential to
establishing a transcatheter valve program. No one
individual, group, or specialty possesses all the necessary
skills for the best patient outcomes.5 The overarching goal
of these programs must be to provide the best possible
patient-centered care.6
Since these are new techniques, the correlation between
operator experience and performance metrics for these
procedures has yet to be established. The current pool of
trained individuals is composed predominantly of those
who have participated in industry-sponsored trials aimed
at device approval. Therefore, the translation of currently
available experiences with transcatheter valve therapies to
the ‘‘real world’’ has yet to be evaluated in theUnited States.
Several core concepts should be implemented for all
physicians performing these procedures, irrespective of
their specialty background.7,8 They should all possess
extensive knowledge of valvular heart disease, including
the natural history of the disease, hemodynamics,
appropriate diagnostics, optimal medical therapy, the
application and outcome of invasive therapies, and
procedural and perioperative care.9
The ability to interpret echocardiographic and other radio-
graphic images (obtained at baseline, during the procedure
and follow-up) is critical. Procedural echo guidance is critical
to the procedural success and the procedural
echocardiographer must be highly skilled. MDTs and
procedural teams need to possess skills to acquire and
interpret transthoracic and transesophageal studies. The use
of 3Dechocardiography is essential. Expertise in the interpre-
tation of CT scans of the ilio-femoral vessels, cardiac anat-
omy, as well as aortic, mitral, and pulmonary valvular
anatomy is critical for determining patient eligibility and
the best approach and type of invasive procedure.10,11
As noted, there is as yet no demonstrated direct correlation
between operator experience with specific procedures and
the skills necessary to perform transcatheter valve proce-
dures. Furthermore, the specific skills required for each pro-
cedure are different. There are, however, some core concepts
that professional societies have accepted as important for
both facilities and operators.12,13 Minimum training for
specific procedures and devices will, for the immediate
future, be primarily dictated by FDA approval
requirements. Simulation should play a significant role in
technical training and proficiency maintenance for these
evolving procedures.14-18 As the procedures becomeery c August 2014
TABLE 1. Mitral valve institutional and operator requirements
Institutional 1000 Cath/400 PCI per year*
Interventionalist 50 Structural procedures per year (including ASD/PFO and trans-septal punctures)
Suitable training on devices to be used
Surgical program 25 Total mitral valve procedures per year, of which at least 10 must be mitral valve repairsy
All cases must be submitted to a single national database
Existing programs 15 Mitral (total experience)
Ongoing CME (or nursing/technologist equivalent) of 10 h per year of relevant material
All cases must be submitted to a single national database
New programs Because the indications are not defined, no volume criteria can be proposed yet
Assuming approval would be for high-risk cohorts, 10%-15% mortality rate at 30-d, similar to registry or published data
65% 1-y survival rate
Ongoing CME (or nursing/technologist equivalent) of 10 h per year of relevant material
All cases must be submitted to a single national database
Training Operator must be board certified in interventional cardiology or board certified/board eligible in pediatric cardiology or similar boards
from outside the United States. Cardiac surgeons must be board certified in thoracic surgery, or similar foreign equivalent.
*With acceptable outcomes for conventional procedures compared to NCDR benchmarks. yMitral valve procedures should be those done for severe mitral regurgitation. Mitral
valve procedures for mild or moderate mitral regurgitation done at the time of other cardiac surgical procedures (AVR, CABG) do not meet this criterion.
Tommaso et al Clinical Guidelinesintegrated into mainstream care delivery, the strategy for
training will likely need to be revised.
Minimum requirements for transcatheter valve therapies
include an understanding of basic radiation safety
necessary for optimal imaging, operator and patient
exposure protection, and knowledge of the use of X-ray
contrast agents, which may not be standard in cardiac
surgery training and experience.
Training in the use of closed systems for hemodynamic
monitoring and contrast injections will result in optimal
integration into catheterization laboratories and hybrid
environments. Catheter and wire skills, including
knowledge of the use of various techniques and the
equipment available to access complex anatomy and
negotiate vascular and anatomic structures, are required.
Understanding of the interplay of wires, catheters, and
anatomy is required for completion of these procedures.
These skills can be acquired in a variety of ways. Prior
experience with a variety of interventional techniques is
important. These include but are not limited to:
 Coronary diagnostic procedures
 Coronary interventions
 Peripheral vascular diagnostic procedures
 Peripheral vascular interventions
 Balloon aortic, mitral and pulmonic dilatation
 Stent implantation in right ventricle outflow tract and
pulmonary arteries
 IABP and other cardiac support device placement,
including initiation of percutaneous cardiopulmonary
bypass
 pVAD placement
 EVAR or TEVAR procedures
 Transseptal techniques
 Coronary sinus access
 Large vessel access and closureThe Journal of Thoracic and CaThe experience of an interventionalist or surgeon should
be relevant to the transcatheter valve procedure undertaken.
For example, primary valve experience with aortic valve
replacement should not be considered adequate experience
for the performance of transcatheter mitral valve repair,
because skill sets for one valve type do not necessarily
translate to another valve type.
The application of sterile techniques, consistent with
operating rooms standards, must be applied to these
procedures and team members.
As one of the leaders of the team performing these
procedures, the interventionalist must be able to enforce
compliance with these standards. These procedures may
involve open or partially open surgical components.
Operating theater standards for sterile technique are
therefore mandatory to ensure optimal patient outcomes.
FACILITIES
The institution should have an active valvular heart
disease surgical program with at least two institutionally
based cardiac surgeons experienced in valvular surgery,
and should contain a full range of diagnostic imaging and
therapeutic facilities, including:
1. Cardiac catheterization laboratory or hybrid operating
room/cath lab equipped with a fixed radiographic imag-
ing system with flat-panel fluoroscopy offering catheter-
ization laboratory-quality imaging. A bi-plane unit may
be advantageous, particularly for congenital heart dis-
ease.
2. Non-invasive imaging
a. Echocardiographic laboratory. Transthoracic and
transesophageal echocardiographic capabilities with
sonographers and echocardiographers experienced
in valvular heart disease. Access to 3D echocardiog-
raphy is necessary.rdiovascular Surgery c Volume 148, Number 2 389
Clinical Guidelines Tommaso et alb. Vascular laboratory (non-invasive) with vascular
specialists capable of performing and interpreting
vascular studies.
c. CT laboratory with CT technologists and specialists
who can acquire and interpret cardiac CT studies.
3. Physical space—The implantation suite must have
a sterile environment that meets operating room
standards. Furthermore, it must have sufficient space to
accommodate the necessary equipment for uncompli-
cated implantations as well as any additional equipment
that may be necessary in the event of complications.
Space for anesthesiology, echocardiography, and
cardiopulmonary bypass equipment and personnel
is essential. A specifically designed hybrid OR
interventional suite is ideal; however, in the absence of
such a facility, the interventional cardiac suite should
have:
a. Circulating HVAC laminar flow diffusers (providing
smooth, undisturbed air flow and usually placed
directly over the procedure table) to meet air
requirements for surgery rooms.
b. Asymmetrical/symmetrical 6-lamp 2 3 4 troffers
(the inverted, usually metal trough suspended from
the ceiling as a fixture for fluorescent lighting) to
provide adequate high-output lighting for surgical
interventions.
c. An adequate number of power receptacles that meet
surgical equipment requirements.
d. For existing mitral valve procedures, cardiopulmo-
nary bypass is almost never needed, but the room
will likely be used for multiple types of structural
procedures and with evolving techniques CPB may
be more frequently necessary, thus adequate space
to run the CPB machine in the interventional suite
is desirable.
e. Gas outlets for the anesthesia machine.
f. An adequate room size to accommodate the standard
equipment required in a cardiac catheterization
laboratory (eg, HD displays and monitors, O2
analyzer, defibrillator/resuscitation cart, O2 supply,
suction, compressed air, CO-oximeter, ACTanalyzer).
4. Minimum room size of 800 square feet (74.3 m2) to
accommodate echocardiographic equipment, sonogra-
phers, anesthesia equipment, the emergency CT sur-
gical team, and cardiopulmonary bypass equipment
(eg, surgeon, assistant, scrub tech, pump techs), if
needed. Although in mitral cases, the need for emer-
gent cardio-pulmonary bypass is minimal, the expec-
tation is that this room will serve for other valvular
procedures and the ability to convert to an OR is
appropriate.
5. Equipment—The interventional suite should stock a
large variety of interchangeable equipment, including390 The Journal of Thoracic and Cardiovascular Surgvarious access kits, endovascular sheaths, and intro-
ducers ranging from 4 Fr to 26 Fr in various lengths,
a wide range of guide wires for various purposes, car-
diac diagnostic and interventional catheters, vascular
closure devices, balloon dilatation catheters ranging
from 2 mm to 30 mm in diameter and of various
lengths and profiles, bare metal and covered stents
(coronary and peripheral), occlusive vascular devices,
snares and other retrieval devices, drainage catheters,
and various implantable device sizes with their delivery
systems.
6. Post-procedure intensive care facility with personnel
experienced in managing patients who have undergone
conventional open-heart valve procedures.
7. Use of a mobile C-arm imaging system in an operating
room is not adequate.
8. HYBRID OR—The Cath Lab Standards Document has
outlined the specifications for a hybrid Cath Lab.19
Most importantly, there must be dedication on the part of
the hospital to provide these services and support, both
financially and with no time constraints on the personnel
involved. A dedicated administrator as a member of the
team is necessary.
OTHER INSTITUTIONAL RESOURCES–
FACILITIES, EQUIPMENT (DISPOSABLES AND
CAPITAL EQUIPMENT), PERSONNEL, SUPPORT,
AND COMMITMENT
For pre- and post-procedure care and joint formal
multidisciplinary patient consultation, adequate outpatient
clinical care facilities are necessary. Appropriate office
space for the medical, nursing, and technical personnel
involved is also required, preferably in a central
setting. Ancillary testing facilities (pulmonary function,
echocardiography, vascular duplex scanning, clinical
laboratory, MSCT) should be of high quality and be able
to accommodate the patient load in a timely manner.
By their very nature, these complex procedures should
only be performed in institutions that currently and
routinely carry out relatively high volumes of surgical
aortic, pulmonic, tricuspid, and mitral valve operations
with established and verifiable track records of optimal
surgical and interventional cardiology outcomes. Similarly,
only institutions with interventional cardiology programs
that have established and successful track records with
balloon aortic and mitral valvuloplasty, catheter closure of
periprosthetic valvular leaks, trans-septal procedures,
insertion of atrial or ventricular septal closure devices,
etc, should develop an integrated structural heart MDT.
The institutional commitment required for a successful
program goes beyond the necessary space, personnel, and
specialized facilities set forth above. The complex
and time-consuming pre-procedure patient triage processery c August 2014
Tommaso et al Clinical Guidelinesand the amount and intensity of post-procedure patient care
after discharge are labor intensive for the physicians,
advanced practitioners (NP and PA), and nursing staff, as
are informed consent and communication with patients,
families, and referring providers. Heart Team decision-
making conferences are valuable to patient care; therefore,
future reimbursement models should take these conferences
into consideration when developing policy. In addition to
supporting the core nursing and technical support staff,
arrangements between the institution and the physicians
need to be in place to cover physician efforts dedicated to
non-reimbursable hours of clinical care and medical
management of the program.
The complexity of transcatheter valve procedures and
the magnitude of institutional resources required are
similar to established heart transplant and cardiac assist
device programs, for which dedicated professionals,
a minimum of infrastructure, a multidisciplinary team,
RN/NP/PA, providers, coordinators, databases, and
quality reporting are essential for optimal patient outcomes.
This concept was endorsed by the Centers for Medicare
and Medicaid Services through the establishment of
certification criteria for the use of heart transplantation
and cardiac assist devices in centers and, moreover, for
eligibility for reimbursement of services provided. The
same regulatory system was applied to professionals
providing these services. Transcatheter valve treatment
programs should undergo a similar regulatory process
with CMS endorsement. Centers should be approved
for specific transcatheter valve programs (aortic, mitral,
and/or pulmonic) based on a minimum number of cases
per year, and perioperative and 1-year outcomes above a
minimum threshold.
Long-term outcome reporting is obligatory in order to
track not only survival, but also parameters including
periprocedural complications (eg, CVA, vascular, renal,
infectious), mitral regurgitation (MR), the need for
intervention, subsequent surgery, and quality of life. This
type of reporting is essential because long-term outcome
goals for these new procedures have not been established
at this early stage. Development of a national data registry
and participation by all institutions are mandatory.
MULTIDISCIPLINARY TEAM
The use of a team approach has been shown to improve
outcomes in these types of complex procedures.20 The
MDT necessary for an interventional valve therapy program
involves far more than just a collaboration between the
interventional cardiologist and cardiac surgeon. In addition
to the individual physicians, components that extend to
various departments are necessary. The idea that the MDT
is composed of individual physicians working in a room
performing the procedures is a superficial view that doesThe Journal of Thoracic and Canot take into account the level of resources necessary for
a successful valve therapy program. The interaction among
specialists in the MDT is fundamental, particularly for
pre-procedure patient evaluation and selection. While there
is great excitement about the application of transcatheter
valve therapies, most of these therapies will only be indi-
cated for a small portion of the population for the immediate
future. Proper decision-making and determination of best
options for any given patient require an evaluation by the
MDT.21
On-site valve surgery is an essential component of any
valve therapy program. The requirement for on-site valve
surgery is based not only on the potential need for emer-
gency or ‘‘back-up’’ surgery for percutaneous patients, but
more importantly on the quality of patient evaluation and
selection, decision-making, intra-procedure management,
and post-procedure care and outcomes.
A cardiac surgeon and an interventional cardiologist
must evaluate every case. The interplay between interven-
tional cardiologists and cardiac surgeons represents only
part of the benefit of the MDT. Additional critical contribu-
tions are provided by cardiac anesthesiology, imaging
specialists in both cardiology and radiology, and by the
many people beyond the physician members of the
team. The MDT is led by a core group of physicians
from interventional cardiology, cardiac surgery, cardiac
anesthesiology, and intensive care and cardiac imaging
departments, along with congenital heart disease
specialists and surgeons. Depending on the institutional
organization and the needs of the patient, vascular surgery
and interventional radiology departments will also
participate in the MDT in many situations. Additional
team members include nurse practitioners from all of
these fields, data/research coordinators, and a dedicated
administrator.
The function of the MDT is essential in pre-procedure
patient selection, intra-procedure management and
problem solving, post-procedure management, post-
discharge follow-up, and outcome studies. During
procedures, emergencies or unanticipated needs may arise
as a matter of course, even in the most straightforward
situation; this is a familiar situation for proceduralists in
any field. The rapid availability of the MDT support to
help with decision-making or with therapy is essential. A
clear definition of roles for the various specialties as well
as effective communication, which may be different
from that for conventional procedures, is critical for
successful outcomes. A difficult course post-procedure is
common in the high-risk patients who comprise a
large part of the target population for both transcatheter
and operative valve therapies. A team approach to
problem solving in this setting is critical. Another
important part of patient management is the familiarityrdiovascular Surgery c Volume 148, Number 2 391
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floor staff have with the specific details of each form of
valve therapy. After the post-procedure management
phase, long-term follow-up for this select group of
patients is also part of the MDT’s responsibility.
Post-approval registries will be required for many of the
new transcatheter valve therapies, and therefore, a data
collection/research unit within the MDT is another required
component.
For sites with no prior trial experience in mitral,
transcatheter therapies, background experience with related
procedures is important. Surgical mitral procedures and
trans-septal puncture procedures are essential background
elements necessary for mitral therapy programs. For trans-
catheter procedures that do not directly involve the surgeon
as a procedure operator, the role of the cardiac surgeon re-
mains critically important. The surgeon has many roles and
is often a patient advocate and/or referring physician, may
be the primary operator and is a necessary scientific study
participant in all of these device applications. The surgeon
is familiar with established standards of care for application
of transcatheter therapies and is frequently in charge of
assessing high-risk patients for catheter-based therapy as
an alternative to surgery. In a valve therapy program, patient
assessment is a multidisciplinary undertaking.
Another mechanism for promoting a team approach that
involves both surgeons and cardiologists is split or shared
physician reimbursement for these procedures, which this
writing group strongly endorses. This important principle
will ensure that surgeons and cardiologists participate
jointly in performing procedures and that each patient
receives the best and most patient-centered treatment.
The MDT should meet formally as a group on a regular
basis (aside from the usual ‘‘cath conference’’) to review
all patients referred for procedures, the performance of
recent procedures (to discuss both good and poor
outcomes), and follow-ups of prior procedures.
FUNCTION OF THE MULTIDISCIPLINARY TEAM
Programmatic success depends on the ability of the MDT
to function effectively in the best interest of a given patient.
To do so, the MDT must work cohesively through the
processes of patient selection, procedural planning,
procedural conduct, periprocedural care, and longitudinal
follow-up. Through each phase of this continuum, the
individual skills of the MDT members should be brought
to bear upon the process.
The procedural success of transcatheter valve therapies
begins with patient selection. Given the complexity of the
decision-making process surrounding these procedures, all
MDTmembers must provide objective input and judgments
from the outset of a patient evaluation. The patient selection
process may be initiated by the use of regularly scheduled
patient selection conferences attended by all MDT392 The Journal of Thoracic and Cardiovascular Surgmembers. Such conferences are analogous to transplant
patient selection committee meetings, and they provide a
venue in which patient-specific data and imaging are
formally presented and discussed by the MDT. The
respective expertise of each discipline represented among
MDT members may then be synthesized into a patient-
specific recommendation. Each member of the heart team
that evaluates the patient must record his/her opinion and
enter it formally into the patient record.
Direct patient evaluation by cardiologists and cardiac
surgeons may be accomplished jointly and, if possible,
simultaneously in a venue such as a multi-disciplinary valve
program clinic. Not only does such a clinic provide
convenience for many patients, but it also provides an
opportunity for cardiac surgeons and cardiologists to jointly
examine and evaluate complex cases.
In so doing, the expertise and judgment of both
disciplines may be woven into a patient-specific decision.
The participation of anesthesiologists in these clinics may
also be useful.
Following the decision that a given patient is an
appropriate candidate for transcatheter mitral valve therapy,
the procedure must then be carefully planned. Cardiac
surgical teams are familiar with, and routinely use the
concept of, ‘‘pre-procedure briefings,’’ prior to complex
cardiac surgical operations. This should be applied to
structural procedures as well. In such briefings, all team
members (surgeons, interventionalists, anesthesiologists,
perfusionists, nurses, technicians, etc.) discuss the intended
procedure, including the steps of the planned procedure, the
specific tools and equipment needed (beyond those
typically used), the possible complications that may arise
during the course of the procedure, and the contingency
plans that will be implemented should the unexpected
occur. All members of the team can then initiate the planned
procedure with a common understanding of its conduct and
what will happen if the plan needs to change.
Adding the cardiologist and the catheterization team to
this pre-procedure planning and MDT briefing is important
for procedural success. During the procedure, emergency
situations and unexpected needs may arise. The immediate
availability of MDT physician support in emergency
decision-making and therapy is essential. It is therefore
important that the roles of the various specialties be clearly
delineated during pre-procedure planning.
In many cases, the initial post-procedure care should be
provided in an intensive care setting. A team approach to
the care of these patients, and to problem solving, is
important and should include physicians skilled in critical
care medicine. Once inpatients are able to leave the
intensive care environment, they should be attended by a
unit specializing in the care of patients with cardiac
diseases, and this unit should be equipped with telemetry-
monitored beds. Again, a team approach is important forery c August 2014
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physical therapists, and other members must have an
understanding of the pathophysiology of mitral valve
disease as well as the nuances of care for patients
who have undergone cardiac surgery and interventional
cardiology procedures.
The procedural success of transcatheter valve therapies,
including the mitral valve, must be determined via
longitudinal outcomes. Long-term follow-up of these pa-
tients is an important element of the MDT approach.
Post-FDA approval registries will be required for most
transcatheter valve therapies. Therefore, a long-term
relationship between the patient and the MDT must be
established, to undertake the needed alterations in medical
therapy, serial echocardiographic imaging, and monitoring
of devices. Likewise, changes in patient functional status,
heart failure class, potential device-related complications,
and other such conditions must be carefully tracked. Avalve
program clinic can provide a venue for this type of
long-term follow-up.
The post-market surveillance of transcatheter valve
devices will be an extremely important function of the
MDT. Participation in device-specific registries can be
challenging and requires an institutional infrastructure and
commitment that includes experienced data managers
with a background in cardiac disease, funding, office space,
and computer resources. It requires a data coordinating/
clinical research unit with rigorous attention to detail,
and the collection of accurate data as an integral part of
the MDT.
CRITERIA FOR ESTABLISHING A
TRANSCATHETER VALVE PROGRAM AND
MAINTENANCE OF COMPETENCE
An important issue in the establishment of a transcatheter
mitral valve program is the clinical or referral base to ensure
an adequate number of patients to provide for the viability
of a program. Table 1 details the important requirements
for the establishment of a successful transcatheter mitral
valve program.
The surgical program numbers in Table 1 were obtained
by querying the STS database, which revealed that at the
operative numbers noted, there would be approximately
256 sites in 46 states that would qualify.
Once chosen for participation as transcatheter mitral pro-
grams, either as existing programs or as new programs, in
order to maintain ongoing approval for participation, sites
will need to be monitored to ensure that they continue to
satisfy both the volume and outcome criteria as described
in Table 1.
Unlike the significant existing experience with PCI,
where abundant data attest to the relationship between
the volume of procedures and outcomes, there are little
or no data on which to draw conclusions as to theThe Journal of Thoracic and Cavolume–outcome relationship for transcatheter valve
therapy. Therefore, the above recommendations are
constructed to (1) ensure patient safety, (2) demonstrate
that there is a commitment on the part of the institution to
the structural heart disease program, and (3) use existing
volume as a surrogate for an established valve program to
ensure adequate patient volumes for the establishment of
a sustainable transcatheter valve program. As experience
grows and more data become available, these recommenda-
tions will undoubtedly be refined.
TRANSCATHETER MITRALVALVE REPAIR
MR is a common lesion present in up to 24% of adults
with valvular heart disease.21 It is clear from the literature
that valve repair yields superior outcomes to replacement
in patients with degenerative disease, although the benefits
of repair over replacement in patients with functional MR
due to ischemic heart disease or dilated cardiomyopathy
are less clear. Due to a combination of the mitral valve’s
structural complexity, unique anatomic location, and wide
variability of pathology, numerous surgical techniques
have been developed over the past several decades to repair
and replace this valve. It is therefore not surprising that
several innovative concepts for transcatheter mitral valve
therapy have been explored. These transcatheter approaches
can be loosely grouped, based on the anatomic region
targeted for intervention, eg, leaflet repairs, annular repairs,
chordal repairs, and valve implants.
To date, the greatest clinical experience is with leaflet
repairs, namely, percutaneous, edge-to-edge coaptation, in
which the anterior and posterior leaflets of the mitral valve
are approximated to create a double orifice mitral valve and
restore coaptation. This approach is based on the surgical
technique described by Alfieri et al. and has been used for
a variety of pathologic MR disease states.22,23 By far the
greatest transcatheter experience to date has been with the
MitraClip (Abbott Vascular, Santa Clara, Calif), the
clinical results of which were published in the EVEREST
I and II trials and the continued access REALISM
registry.23-25 Intraprocedural patient management requires
the participation of the interventional cardiologist,
echocardiographer, anesthesiologist, and supporting
cardiac surgeon. Other transcatheter procedures focusing
on leaflet modification (such as leaflet ablation and space
occupation between leaflets) or annular reduction are in
various stages of development and are not yet in clinical
practice outside of clinical trials.26-29 It is likely that these
procedures will require similar pre-procedural assessment,
intra-procedural personnel and equipment, operator
experience, and post-procedural assessment and care.
The pre-, intra-, and post-procedure evaluation of MR
patients is arguably the most complex evaluation of the
various valve lesions amenable to any form of transcatheter
therapy. Success will therefore heavily depend on ardiovascular Surgery c Volume 148, Number 2 393
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rapher, clinical cardiologist, cardiac surgeon, and interven-
tional cardiologist. Variations on other techniques for
transcatheter mitral repair are under development and will
be addressed in a future version of these recommendations.
The MitraClip is currently the only mitral valve proce-
dure approved by the FDA. In regards to this procedure,
the collaboration of the cardiothoracic surgeon and
interventional cardiologist will span the pre-, intra-, and
post-procedure care of the patient. The procedure itself is
commonly performed by a single physician. This
physician may be either an interventional cardiologist or a
cardiothoracic surgeon; however, for some patients, the
expertise of two physicians (either two interventional
cardiologists, or an interventional cardiologist and a
cardiothoracic surgeon) could be required. For future
trans-catheter mitral valve replacement, as with
TAVR, the cardiothoracic surgeon and interventional
cardiologist are to be fully involved in all aspects of
care: pre-operative assessment/patient selection, intra-
procedural and post-procedural management and follow-
up. Depending on the nature of subsequently approved
devices, intraprocedural management may require the
simultaneous involvement of an interventional cardiologist
and a cardiovascular surgeon.
NATIONAL REGISTRY
FDA clearance of a novel valve repair or replacement
prosthesis does not guarantee that the device will continue
to demonstrate long-term efficacy equal to currently
available options, or that it will be limited to the initially
approved patient subsets. Post-market studies organized
through individual institutions or multicenter study groups
and registries managed by industry and professional
societies are essential to ensuring continued short-term
safety, and to determining long-term efficacy. Only with
such data can we consider the application of new valve
prostheses to a wider patient population outside the
boundaries of the study groups examined during FDA trials.
Centers that incorporate transcatheter-based therapies into
their practice absolutely must participate in the TVT-
NCDR database. Early post-procedure morbidity and
mortality analyses, while important for initial and continued
implant safety assessment, are not sufficient to evaluate the
efficacy of valve repair or replacement prostheses. Studies
on long-term follow-up survival and, more importantly,
structural valve degeneration, and the need for reinterven-
tion, are essential.
Transcatheter valve repair or replacement devices are
unique in that an understanding not only of early risk, but
also of long-term durability, is essential to determining
the appropriate patient subgroups for these therapies. In
our opinion, it is the responsibility of professional societies
to ensure adequate long-term data monitoring and to394 The Journal of Thoracic and Cardiovascular Surgprovide oversight and guidance to industry on the expecta-
tions for continued monitoring beyond the FDA approval
phase of device development and implementation. Individ-
ual centers are also responsible for critically evaluating
their own experience, through local and regional quality
improvement initiatives, and for participating in national
databases and registries that facilitate continued safety
and efficacy in the assessment of novel and as yet unproven
therapeutic options.References
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